Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) Research

Oxford Cannabinoid Technologies Holdings Plc operates as a pharmaceutical company, focused on the research, development, and commercialization of cannabinoid-derived prescription medications. Their principal drug candidate, OCT461201, is a selective CB2 receptor agonist in an oral solid dosage format, currently undergoing pre-clinical assessment. It is being developed to target visceral pain associated with Irritable Bowel Syndrome (IBS), as well as a range of neuropathic pain conditions, notably post-herpetic neuralgia. The company is also progressing with OCT130401, another compound in pre-clinical development, intended for the treatment of trigeminal neuralgia. Incorporated in 2017, Oxford Cannabinoid Technologies Holdings Plc is based in London, United Kingdom.

Market snapshot

Symbol
OCTP.L
Price
$0.12
Day change
-4.17%
Market cap
$1.3M
P/E ratio
-0.19x
52-week range
0.0-1.375
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Deltex Medical Group plc (DEMG.L)
  • DeepVerge plc (DVRG.L)
  • Hellenic Dynamics Plc (HELD.L)
  • Kanabo Group Plc (KNB.L)
  • LungLife AI, Inc. (LLAI.L)
  • LungLife AI, Inc. (LLA.L)
  • Oncimmune Holdings plc (ONC.L)
  • Ovoca Bio plc (OVB.L)

Open Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.